AstraZeneca, breast cancer
Shares of AstraZeneca PLC AZN inched down 0.54% to £115.22 Tuesday, on what proved to be an all-around positive trading ...
AstraZeneca topped the analyst consensus for net revenue and matched the analyst consensus for core EPS in Q2. See why I ...
The newly launched “What Science Can Do” campaign, a longstanding tagline for AstraZeneca, centers around the stories of two patients who have benefitted from the company’s therapeutics. Each of their ...
The AstraZeneca PLC ADR AZN slipped 1.58% to $77.14 Monday, on what proved to be an all-around great trading session for the ...
AstraZeneca Plc shares are on track for their biggest weekly decline since July 2023, after a disappointing update for the ...
Datopotamab deruxtecan is a TROP2-directed DXd ADC engineered by Daiichi Sankyo and co-developed by AstraZeneca and Daiichi Sankyo. The data pertaining to this compound will be presented at an ...
If approved, AZN's Fasenra will be the second biologic approved in the European Union to treat eosinophilic granulomatosis ...
Astrazeneca Pharma India has received CDSO's (Central Drugs Standard Control Organisation) nod for the import of Durvalumab ...